MetLife, Inc.
—- Market cap
- —
- Debt
- +$14.82B
- Cash
- −$22.03B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: MET stock price vs LNC: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LNC's multiple
Needs LNC P/E.
Implied fair value · at MET's multiple
Needs MET P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
MetLife, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
LINCOLN NATIONAL CORP · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe LNC-implied multiples (and resulting implied price of $13.02, -83.5% downside) are the correct basis for valuation, then reduce or exit long positions because MetLife's current price ($78.88) is far above LNC-implied and implies substantial downside; otherwise, maintain or trim exposure acknowledging that MetLife's scale and high ROIC (33.7%) may justify a premium.
The market price ($78.88) sits well above LNC-implied range ($13.02 - $38.85), producing an implied downside of -83.5% versus the $13.02 LNC-implied price. The gap is driven primarily by LNC-based P/E disconnect (MET P/E 13.3x vs LNC P/E 2.2x) and historical valuation context where the current price sits within MetLife's historical band ($70.99 - $86.77).
Supporting Metrics